It probably started when medical authorities put the blame for heart disease (atherosclerosis) on circulating cholesterol. In the modern era, this goes back to the 1950s or before, when heart disease was still relatively rare, but increasing. Heart disease became publicly prominent in 1955, when US President Eisenhower suffered a heart attack (which he survived).
Briefly, the cholesterol hypothesis proposes that by getting into arterial walls and causing atherosclerosis (plaque buildup in arteries), cholesterol increases the risk of cardiovascular disease (CVD) and cerebrovascular disease (strokes). However, according to a perhaps unlikely source – the American Heart Association: “Exactly how atherosclerosis starts or what causes it isn’t known.” That’s an admission
As long ago as 2005 an audit of just 18 patients, admitted to an emergency department, reported that there were 3,679 pages of clinical guidelines associated with their conditions. Imagine what it is like 13 years later. What started out as support for evidence-based medicine, and as a means for clinicians to keep abreast of
Primary care for cardiovascular disease (CVD) – the prevention of a CVD event in people who have not experienced one before – is an established objective in clinical practice. The premise is that certain health or lifestyle indicators associate with the risk of a future CVD event, such as a heart attack or stroke. It
Statins have become the most profitable class of drugs in the history of medicine, and the most profitable of them all has been Lipitor (Atorvastatin), manufactured by Pfizer (the largest pharmaceutical company by revenue). Here is a Lipitor advertisement from the early 2000’s highlighting that, in patients with multiple risk factors for heart disease, Lipitor